Merck News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

24.05.12	Gericht spricht Dow Chemical 2,2 Milliarden Dollar zu (dpa-afx)
05.10.07	Interim Results from a New Trial of CANCIDAS(R) (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections (Businesswire)
26.09.07	Merck to Donate Three Million Doses of Gardasil(R), its Cervical Cancer Vaccine, to Support Vaccination Programs in Lowest Income Nations (Businesswire)
28.08.07	Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet (PR Newswire)
01.08.07	Seven Summits Research Releases Alerts on T, MRK, DO, CTSH, and WFMI (PR Newswire)
23.07.07	Wall Street: Freundlicher Start in die Woche, Merck und Schering-Plough treiben an (Aktiencheck)
16.07.07	ROTATEQ(R) and GARDASIL(R) Adopted by All Immunization Projects of the Centers for Disease Control and Prevention's (CDC) Vaccines for Children (VFC) Program (Businesswire)
29.06.07	Merck Names Peter Kellogg as Executive Vice President and Chief Financial Officer (Businesswire)
09.05.07	New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine (Businesswire)
30.04.07	Ausblick: Die Märkte am Montag (Aktiencheck)
25.04.07	New Indication for SINGULAIR(R) (montelukast sodium) Approved to Prevent Exercise-induced Bronchoconstriction (Businesswire)
24.04.07	Merck & Co.: CEO Richard T. Clark wird neuer Chairman (Aktiencheck)
02.04.07	Merck & Co erhält US-Zulassung für Janumet (Aktiencheck)
02.04.07	FDA Approves JANUMET(TM) for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet (Businesswire)
28.03.07	Ausblick: Die Märkte am Mittwoch (Aktiencheck)
27.03.07	Merck Wins Product Liability Case in Madison County, Ill. - Schwaller v. Merck (Businesswire)
26.03.07	Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine (Businesswire)
20.02.07	Merck & Co. kündigt Rücktritt von CFO an (Aktiencheck)
13.02.07	Ben-Gurion University of the Negev Deploys Rosetta Biosoftware Systems for a Pilot Study in Bioinformatics (Businesswire)
08.02.07	MEDAL Program Showed Arthritis Patients Taking ARCOXIA(R) (etoricoxib) Experienced Significantly Fewer Upper Gastrointestinal Events Compared to Diclofenac (Businesswire)
30.01.07	Wall Street: Kaum verändert, Procter & Gamble im Blick, UPS und 3M unter Druck (Aktiencheck)
30.01.07	Merck Announces 2006 Financial Results that Demonstrate Solid Revenue Growth (Businesswire)
19.01.07	VIOXX(R) Plaintiffs Failed to Prove Their Cases (Businesswire)
21.12.06	REPEAT/FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults (Businesswire)
20.12.06	FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults (Businesswire)
13.12.06	Merck Wins Federal VIOXX(R) Product Liability Case (Businesswire)
05.12.06	New Data Show Significant Reductions in Both Post-Meal and Fasting Blood Sugar Levels with Sitagliptin Phosphate Plus Metformin as Initial Therapy in Patients with Type 2 Diabetes (Businesswire)
04.12.06	Merck and Neuroptix Collaborate on Early Alzheimer's Diagnostics Using Laser Eye Scanning (Businesswire)
01.12.06	Merck Announces JANUMET(TM), the Trademark for its Investigational Combination Therapy of Sitagliptin Phosphate and Metformin for Type 2 Diabetes (Businesswire)
22.11.06	Statement Regarding Dismissal of Personal Injury Class-Action Lawsuit (Businesswire)
17.11.06	MSD's Prüfsubstanz MK-0524 reduzierte durch Extended-Release Niacin mit Langzeitwirkung hervorgerufene Flushing-Reaktionen in einer Phase II-Studie (Businesswire)
13.11.06	Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine (Businesswire)
03.11.06	Merck & Co., Inc. Introduces New 14th Edition of The Merck Index, with Companion CD-ROM (Businesswire)
20.10.06	Merck & Co.: Vioxx-Skandal belastet Ergebnis (Aktiencheck)
18.10.06	JANUVIA(TM) einmal täglich, der erste und in den USA einzige für Typ-2-Diabetes verfügbare DPP-4-Hemmer (Dipeptidyl-Peptidase-Inhibitor) von der FDA zugelassen. (Businesswire)
09.10.06	FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies (Businesswire)
07.10.06	FDA Approves ZOLINZA(TM) (Vorinostat) for the Treatment of Cutaneous Manifestations in Patients with Cutaneous T-Cell Lymphoma Who Have Tried and Failed Other Therapies (Businesswire)
28.09.06	Ausblick: Die Märkte am Donnerstag (Aktiencheck)
26.09.06	Merck Wins Federal VIOXX(R) Product Liability Case: Smith v. Merck & Co., Inc. (Businesswire)
02.08.06	Merck & Co., Inc. Conference Call and Audio Web Cast (Businesswire)
24.07.06	Merck Announces Strong Financial Results for the Second Quarter 2006 (Businesswire)
17.07.06	Rosetta Biosoftware Licenses the Rosetta Resolver Expression Data Analysis System to University of Nebraska-Lincoln (Businesswire)
13.07.06	Merck Wins New Jersey VIOXX(R) Product Liability Case; Jury Rejects Claims of Long-Term VIOXX User (Businesswire)
29.06.06	CDC Advisory Committee on Immunization Practices Unanimously Recommends Addition of a Second Dose of Chickenpox-Containing Vaccine to Childhood Immunization Schedule (Businesswire)
26.06.06	Merck Stands Behind Original APPROVe Study Results; Increased Relative Risk Observed Beginning After 18 Months (Businesswire)
21.06.06	Phase II Studies Show Investigational Insomnia Agent Gaboxadol Improved Deep Sleep and Key Sleep Measures in Adults with Primary and Transient Insomnia (Businesswire)
19.06.06	REPEAT/New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Significantly More Effective than Crestor(R) (rosuvastatin) at Lowering LDL ''Bad'' Cholesterol At All Doses Compared (Businesswire)
18.06.06	New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Significantly More Effective than Crestor(R) (rosuvastatin) at Lowering LDL ''Bad'' Cholesterol At All Doses Compared (Businesswire)
12.06.06	REPEAT/New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Recommended Usual Starting Doses (Businesswire)
10.06.06	New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Recommended Usual Starting Doses (Businesswire)
09.06.06	FDA Approves New Indication for ZETIA(R) (ezetimibe) - Merck/Schering-Plough's Cholesterol Lowering Drug - For Administration in Combination with Fenofibrate, along With Diet (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

mehr

19.11.24		Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten
19.11.24		Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus
19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Gewinne in New York: NASDAQ 100 legt zu
19.11.24		Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
19.11.24		Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich